Dren Bio
Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.
$350MPrivate financing
ParticipantActivity from announced rounds
Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Draig Therapeutics develops neuropsychiatric medicines.
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
Corxel Pharmaceuticals develops clinical-stage medicines for cardiometabolic diseases, including obesity, diabetes, stroke and hypertension.
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions